What is the risk of diabetic ketoacidosis (DKA) when using Jardiance (empagliflozin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

DKA Risk with Jardiance (Empagliflozin)

Jardiance carries a real but rare risk of diabetic ketoacidosis (DKA), including euglycemic DKA, particularly in patients with insulin deficiency, though this risk is significantly lower in type 2 diabetes compared to type 1 diabetes.

Baseline Risk Assessment

The absolute risk of DKA with empagliflozin in type 2 diabetes is low but measurable. A large multinational study found empagliflozin increased DKA risk approximately 2-fold compared to DPP-4 inhibitors (adjusted incidence rate ratio 2.19,95% CI 1.74-2.76) 1. However, the overall incidence remains rare at approximately 0.43% among all SGLT2i users 2.

The 2025 ADA guidelines explicitly acknowledge this risk, stating DKA can occur "in individuals with insulin deficiency (rare in T2D)" 3. The FDA label for Jardiance emphasizes that ketoacidosis can occur even with blood glucose less than 250 mg/dL (euglycemic DKA), which is the most dangerous presentation because it delays diagnosis 4.

High-Risk Populations Requiring Extra Caution

Do not use or immediately discontinue empagliflozin in patients with:

  • Type 1 diabetes (contraindicated per FDA label) 4
  • Active DKA or history of DKA
  • Severe insulin deficiency (C-peptide negative, low insulin requirements)
  • Hematologic malignancies undergoing intensive treatment 5

Exercise extreme caution and consider alternative agents in:

  • Patients on immunotherapy (particularly pembrolizumab), where fulminant euglycemic DKA has been reported 6
  • Cancer patients with reduced oral intake, weight loss, or frequent infections 5
  • Patients following ketogenic diets 7
  • Those with recurrent infections or frequent illness 2

Critical Risk Mitigation Strategies

Mandatory discontinuation scenarios per ADA guidelines and FDA labeling 3, 4:

  • 3-4 days before scheduled surgery
  • During critical illness or hospitalization for acute conditions
  • During prolonged fasting or inability to maintain oral intake
  • With severe vomiting, diarrhea, or dehydration
  • If any symptoms of DKA develop

Patient education must include recognition of DKA symptoms:

  • Nausea and vomiting
  • Abdominal pain
  • Unusual fatigue
  • Difficulty breathing

Key teaching point: These symptoms warrant immediate medical evaluation even if blood glucose is normal (euglycemic DKA presentation).

Comparative Risk by SGLT2i Agent

Among SGLT2 inhibitors, canagliflozin appears to carry the highest DKA risk (100% euglycemic DKA in one cohort), followed by empagliflozin (77%), then dapagliflozin (48.3%) 2. However, empagliflozin remains a reasonable choice given its robust cardiovascular and renal benefits 3.

Special Clinical Scenarios

During acute heart failure hospitalization: Recent data suggests empagliflozin may be safe, with DKA rates of only 0.1% (identical to non-exposed patients) during hospitalization for acute heart failure 8. This supports continuing therapy in stable hospitalized patients without other DKA risk factors.

Infection as a trigger: Infection is the most common precipitant of DKA in SGLT2i users (32.6% of cases), and is specifically associated with hyperglycemic rather than euglycemic DKA 2. Patients should have a sick-day plan that includes temporarily holding empagliflozin during acute infections.

Practical Clinical Algorithm

  1. Before prescribing: Screen for insulin deficiency markers (low C-peptide, minimal insulin requirements, autoantibodies)
  2. At initiation: Provide written sick-day instructions emphasizing medication discontinuation
  3. Ongoing monitoring: Assess for weight loss, dietary changes, and infection frequency
  4. Pre-procedure: Stop 3-4 days before elective surgery 3
  5. If DKA suspected: Check urine ketones or serum beta-hydroxybutyrate regardless of glucose level 4

Common Pitfalls to Avoid

  • Assuming normal glucose excludes DKA: Euglycemic DKA (glucose <250 mg/dL) is the predominant presentation with SGLT2i 2, 7
  • Continuing during acute illness: This is the most preventable cause of SGLT2i-associated DKA
  • Inadequate patient education: Patients must understand to stop the medication when sick and recognize DKA symptoms
  • Using in unrecognized type 1 diabetes: Adults with low insulin requirements should prompt diabetes phenotype reassessment 7

The cardiovascular and renal benefits of empagliflozin generally outweigh DKA risk in appropriate type 2 diabetes patients 3, 1, but meticulous patient selection and education are non-negotiable for safe use.

References

Related Questions

What is euglycemic diabetic ketoacidosis caused by empagliflozin?
In a hyperglycemic patient with elevated blood glucose and ketonuria, should I hold Jardiance (empagliflozin)?
What are the clinical features of diabetic ketoacidosis in a patient taking Jardiance (empagliflozin)?
How should I manage euglycemic diabetic ketoacidosis caused by empagliflozin—should I use an intravenous insulin infusion instead of a subcutaneous sliding‑scale regimen, and what fluid and electrolyte protocol is recommended?
Do patients experience polydipsia (thirst) when they develop euglycemic diabetic ketoacidosis (DKA) while taking Jardiance (empagliflozin)?
In an 80‑year‑old patient with morning hand stiffness, right ankle pain and swelling, a normal uric acid level, and a positive rheumatoid factor, what is the most likely diagnosis and recommended initial treatment?
Which selective serotonin reuptake inhibitors (SSRIs) are approved for the treatment of post‑traumatic stress disorder (PTSD)?
How can I use weight changes, blood urea nitrogen (BUN), creatinine, serum osmolality, and estimated glomerular filtration rate (eGFR) to determine whether a patient in a skilled nursing facility is volume depleted?
What is the differential diagnosis for an extramedullary calcified lesion on the posterior aspect of the C1 spinal canal?
What is the appropriate management for a 36-year-old woman with a one-month cough, persistent sore throat, rhinorrhea, fever, and myalgias despite prior corticosteroid injection and amoxicillin therapy?
What dose of methylprednisolone can be given?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.